Cholera/enterotoxigenic Escherichia coli vaccine - Celldex Therapeutics

Drug Profile

Cholera/enterotoxigenic Escherichia coli vaccine - Celldex Therapeutics

Alternative Names: Cholera/ETEC vaccine; Combined ETEC-cholera vaccine [Peru-15-pCTB (Cholera toxin B-subunit)] - Celldex/NIAID; Combined live, attenuated, enterotoxigenic Escherichia coli (ETEC)-cholera Vaccine (Peru-15 pCTB) - Celldex Therapeutics/NIAID; ETEC/cholera vaccine; Peru-15 pCTB; Traveller's diarrhoea vaccine - Celldex Therapeutics

Latest Information Update: 14 Feb 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Celldex Therapeutics Inc
  • Developer Celldex Therapeutics Inc; National Institute of Allergy and Infectious Diseases
  • Class Cholera vaccines; Escherichia coli vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Phase I Cholera; Escherichia coli infections

Most Recent Events

  • 03 Feb 2011 NIAID completes a Phase-I clinical trial in the prevention of Escherichia coli infections and cholera (in volunteers) in USA (PO)
  • 24 Jun 2010 NIAID completes enrolment in its phase I trial in healthy volunteers in USA (NCT00654108)
  • 23 Jan 2009 E.coli vaccine licensed to Vaccine Therapeutics worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top